The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach

Conditions:   Granulomatosis With Polyangiitis;   Wegener Granulomatosis;   VasculitisInterventions:   Drug: 5 mg prednisone;   Drug: 0 mg prednisoneSponsors:   University of South Florida;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   Office of Rare Diseases (ORD);   National Center for Advancing Translational Science (NCATS);   Rare Diseases Clinical Research NetworkRecruiting - verified December 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials